Follistatin is a useful biomarker predicting the effect of sorafenib for the treatment of hepatocellular carcinoma with extrahepatic spread

被引：0
|
作者：
Adachi, Takuya [1 ]
Nouso, Kazuhiro [1 ]
Okada, Hiroyuki [1 ]
机构：
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama, Japan
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2017年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P-0094
引用
收藏
页码：157 / 158
页数：2
相关论文
共 50 条
  • [31] Effect of sofosbuvir and ribavirin on therapeutic efficacy of sorafenib in the treatment of hepatocellular carcinoma
    Rana, A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 58 - 58
  • [32] Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells
    Wu, Man
    Zhao, Guanren
    Zhuang, Xiaomei
    Zhang, Tianhong
    Zhang, Ce
    Zhang, Wenpeng
    Zhang, Zhenqing
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 2945 - 2954
  • [33] Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study
    Natsuhiko Shirota
    Kazuhiro Saito
    Katsutoshi Sugimoto
    Kenichi Takara
    Fuminori Moriyasu
    Koichi Tokuuye
    [J]. Cancer Imaging, 16
  • [34] Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study
    Shirota, Natsuhiko
    Saito, Kazuhiro
    Sugimoto, Katsutoshi
    Takara, Kenichi
    Moriyasu, Fuminori
    Tokuuye, Koichi
    [J]. CANCER IMAGING, 2016, 16
  • [35] Treatment of advanced hepatocellular carcinoma: beyond sorafenib
    Meyer, Tim
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (04): : 218 - 220
  • [36] Guidelines for treatment of hepatocellular or renal carcinoma with sorafenib
    Rosmorduc, O.
    Chevreau, C.
    Dielenseger, P.
    Ederhy, S.
    Goldwasser, F.
    Grange, J. -D.
    Mortier, L.
    Neidhardt-Berard, M. -E.
    Robert, C.
    Scotte, F.
    Seitz, J. -F.
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2010, 34 (03): : 161 - 167
  • [37] Adverse events of sorafenib in hepatocellular carcinoma treatment
    Pang, Yongsheng
    Eresen, Aydin
    Zhang, Zigeng
    Hou, Qiaoming
    Wang, Yining
    Yaghmai, Vahid
    Zhang, Zhuoli
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (06): : 2770 - 2782
  • [38] Sorafenib for Treatment of Hepatocellular Carcinoma: A Systematic Review
    Xie, Bingru
    Wang, David H.
    Spechler, Stuart Jon
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2012, 57 (05) : 1122 - 1129
  • [39] The screening of sorafenib analogs for the treatment of hepatocellular carcinoma
    Yu, J.
    Dar, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S77 - S77
  • [40] Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
    Almhanna, Khaldoun
    Philip, Philip A.
    [J]. ONCOTARGETS AND THERAPY, 2009, 2 : 261 - 267
12345